research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
==== Male reproductive system ==== The effect of estradiol (and estrogens in general) upon male reproduction is complex. Estradiol is produced by action of aromatase mainly in the Leydig cells of the mammalian testis, but also by some germ cells and the Sertoli cells of immature mammals. It functions (in vitro) to prevent apoptosis of male sperm cells. While some studies in the early 1990s claimed a connection between globally declining sperm counts and estrogen exposure in the environment, later studies found no such connection, nor evidence of a general decline in sperm counts. Suppression of estradiol production in a subpopulation of subfertile men may improve the semen analysis. Males with certain sex chromosome genetic conditions, such as Klinefelter's syndrome, will have a higher level of estradiol.
=== Off-label drugs === α2-Adrenergic receptor antagonists (e.g., yohimbine, rauwolscine (found in yohimbe)) – erectile dysfunction, low sexual desire Androgens/anabolic steroids (androgen receptor agonists) (e.g., testosterone, testosterone esters, methyltestosterone) – low sexual desire Antiandrogens (e.g., GnRH modulators, high-dose estrogen therapy, high-dose progestogen therapy) – various mechanisms of action – paraphilias, hypersexuality, sexual deviance Antipsychotics (e.g., haloperidol) – dopamine receptor antagonists, other actions – paraphilias, hypersexuality, sexual deviance Bupropion (Wellbutrin, Zyban) – norepinephrine–dopamine reuptake inhibitor (NDRI), other actions – low sexual desire Buspirone (Buspar) – serotonin 5-HT1A receptor agonist, other actions – low sexual desire Clomipramine (Anafranil) – tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions – premature ejaculation Cyproheptadine (Periactin) – non-selective serotonin receptor antagonist, other actions – anorgasmia, low sexual desire/decreased libido Estrogens (e.g., estradiol, estradiol esters, ethinylestradiol) – estrogens (estrogen receptor agonists) – atrophic vaginitis, dyspareunia, vulvodynia, low sexual desire Horny goat weed (Epimedii herba) – unknown mechanism of action – low sexual desire Selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluoxetine, paroxetine, citalopram, escitalopram) – premature ejaculation, paraphilias, hypersexuality, sexual deviance Selegiline (L-deprenyl; Eldepryl, Zelapar, Emsam) – monoamine oxidase B (MAO-B) inhibitor, other actions – low sexual desire Tramadol (Tramal) – μ-opioid receptor agonist, serotonin–norepinephrine reuptake inhibitor (SNRI), other actions – premature ejaculation Trazodone (Desyrel, Oleptro) – serotonin antagonist and reuptake inhibitor (SARI), various actions – erectile dysfunction, low sexual desire
== Commentary on COVID-19 in New Zealand == In May 2020, Turner, speaking as director for the Immunisation Advisory Centre, supported the use of a vaccine in managing the COVID-19 pandemic in New Zealand and highlighted that it was important to avoid issues of equity of access across the world by privileging the wealthier nations. She concurred with other experts that the vaccine was a key component in responding to the virus and cautioned against unrealistic hopes that it would happen quickly in New Zealand because of supply issues and prioritisation of the administration to the most vulnerable, and those at "heightened risk of infections like border workers and health staff". When New Zealand confirmed the purchase of the Pfizer COVID-19 vaccine, Turner said that while the country had access to both clinical and "real world" data, and was well situated to approve it, there was no need to rush the process. She noted that because there was little "severe illness and death from this disease" in New Zealand, the country was in the privileged position of being able to "scrutinise the science, watch how the vaccine rollout goes for other countries." To Turner, the rollout of a vaccine in New Zealand would be planned and sequential, aiming ultimately for widespread community vaccination.
Sources: en.wikipedia.org
== Secretion efficiency determination == Signal peptides are extremely heterogeneous, many prokaryotic and eukaryotic ones are functionally interchangeable within or between species and all determine protein secretion efficiency.
=== Importance in cancer biology === ITGA1 has shown to be an important regulator of cancer progression because malignant cells frequently exploit integrin-mediated ECM signaling to promote survival, invasion, metastasis, and therapy resistance. Dysregulated integrin signaling is associated with tumor development across multiple types of cancer, making ITGA1 a potential biomarker and therapeutic target. In PDAC, ITGA1 contributes to tumor progression by linking collagen-rich ECM environments with intracellular signaling pathways that support EMT, metastatic dissemination and survival. ITGA1 was identified as part of a protein network associated with PDAC progression emphasizing its importance in tumor biology. In retinoblastoma, ITGA1 is a possible therapeutic target because ITGA1 expression promotes the same functions of tumor cells through activation of downstream signaling pathways like FAK and STAT3. Pharmacological or genetic inhibition of ITGA1 reduces tumor progression, exhibiting the potential importance of targeting ITGA1-associated signaling pathways in pediatric cancers. In glioma, ITGA1 contributes to treatment resistance by promoting cell survival signaling. Increased ITGA1 activity supports activation of the PI3K/AKT pathway and anti-apoptotic signaling through Bcl-2, promoting resistance toward temozolomide. The involvement of ITGA1 in drug resistance highlights its role in regulating tumor cell adaptation to therapeutic stress.
In contrast to mirtazapine, the selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and some tricyclic antidepressants acutely increase the general activity of the 5-HT2A, 5-HT2C, and 5-HT3 receptors, leading to a number of negative changes and side effects, the most prominent of which include anorexia, insomnia, nausea, and diarrhea, among others. However, most of these adverse effects are temporary, since down regulation of 5-HT2A receptors eventually occurs following chronic SSRI treatment, and desensitization of 5-HT3 receptors often occurs within a week or less. This is precisely why SSRIs have a delayed antidepressant and anxiolytic effect, and occasionally, an acute anxiogenic effect before down regulation occurs. Mirtazapine, on the other hand, is an antagonist of the 5-HT2A receptor, and antagonists at this receptor typically induce reverse tolerance. Thus, the antidepressant and anxiolytic effects of mirtazapine occur more rapidly than with SSRIs. Furthermore, its reduced incidence of sexual dysfunction (such as loss of libido and anorgasmia) could be a product of negligible binding to the serotonin transporter and antagonism of the 5-HT2A receptors; however, Mirtazapine's high affinity towards and inverse agonism of the 5-HT2C receptors may greatly attenuate those pro-sexual factors (as evidenced by the pro-sexual effects of drugs like m-CPP and lorcaserin which agonize 5-HT2C receptors in a reasonably selective manner).
=== Shooting of student at law school === Duterte stated at a rally in April 2016 that he shot a fellow student who had bullied him about his Visayan origin as well as other students of the same ethnicity, while at San Beda law college. He said, "But the truth is, I'm used to shooting people. When we were about to graduate from San Beda, I shot a person." Duterte said that he shot the student in a corridor at the college when the said student called him names again. He later told a reporter that the student survived, but refused to answer any further questions about the incident. However, in an interview aired on 24 Oras and published on the official GMA News Online website on April 22, 2016, retired labor arbiter Arthur Amansec said Duterte and Octavio Goco at that time were both playing with a gun as it was normal for students to bring guns to school in the seventies. Amansec is Duterte's former classmate in San Beda College who witnessed the incident. He added that "the bullet hit the school's wooden floor and was embedded there." Amansec emphasized that Duterte and Goco remained friends until Goco died in the United States years later.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.